{"entity":{"id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","aka":[],"tldr":"A phase 1/2 trial of JDQ443, Trametinib, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.","summary":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments is a phase 1/2 interventional study registered as NCT07468071 by Novartis Pharmaceuticals, with 40 participants planned, started 2026-06-08 and due to reach its primary completion in 2029-06-11. Interventions recorded: Opnurasib, TNO155, trametinib, cetuximab, tislelizumab. Conditions listed: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07468071","url":"https://clinicaltrials.gov/study/NCT07468071"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["jdq443","trametinib","cetuximab","tislelizumab"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07468071","phase":"1/2","setting":"KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments","sponsor":"Novartis Pharmaceuticals","enrolled":40,"outcomes":[]},"route":"/trials/nct07468071/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"jdq443","kind":"drug","name":"JDQ443","route":"/drugs/jdq443/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"},{"id":"tno155","kind":"drug","name":"TNO155","route":"/drugs/tno155/"},{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}